

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

### **INNOVATIVE DRUG “SYHA1805” OBTAINS CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “SYHA1805” (the “**Product**”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is a new type of small-molecule agonist and currently there is no product of the same type available in the global market. The clinical indication for this approval is treatment of non-alcoholic steatohepatitis (NASH). The pre-clinical studies have shown that the Product has a high selectivity of efficacy targets, can significantly ameliorate liver fibrosis and has excellent in vivo and in vitro activities as well as good safety, providing a promising prospect of demonstrating good efficacy in the clinical trials.

The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 28 May 2020

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*